Target and Its Patented Drug(s)
| Target General Information | Top | ||||
|---|---|---|---|---|---|
| Target ID | T80959 | Target Info | |||
| Target Name | Keap1-Nrf2[DLG] PPI (KEAP1-Nrf2 DLG) | ||||
| Synonyms | Kelch-like protein 19-Nrf2[DLG]; Kelch-like ECH-associated protein 1-Nrf2[DLG]; KLHL19-Nrf2[DLG]; KIAA0132-Nrf2[DLG]; INrf2-Nrf2[DLG]; Cytosolic inhibitor of Nrf2-Nrf2[DLG] | ||||
| Target Type | Patented-recorded Target | ||||
| Gene Name | KEAP1-NFE2L2 | ||||
| UniProt ID | |||||
| Patent(s) and the Corresponding Patented Drug(s) | Top | ||||
|---|---|---|---|---|---|
| World Intellectual Property Organization (WIPO) | |||||
| Patent ID | WO2014197818 | ||||
| Title | Small Molecule Activators of Nrf2 Pathway. | ||||
| Abstract | This disclosure relates to compounds that act as activators of the NRF2/KEAP1/ARE pathway. Specifically, the compounds provided herein can act as high affinity reversible bindings for the NRF2 inhibitor, KEAP1. In some cases, NRF2/KEAP1/ARE pathway activation compounds are capable of repressing expression of inflammatory markers and/or reducing levels of TNFa to provide neuroprotective anti-inflammatory effects in the CNS. Such compounds are useful in the treatment of a variety of diseases including Huntington's disease, Parkinson's disease, Alzheimer's disease, inflammation, and cancer. | ||||
| Applicant(s) | The General Hospital Corporation | ||||
| Representative Drug(s) | D09MSN | Drug Info | N.A. | Click to Show More | [1] |
| 2 | D0AR0L | Drug Info | N.A. | [1] | |
| 3 | D0I2DV | Drug Info | N.A. | [1] | |
| References | Top | ||||
|---|---|---|---|---|---|
| REF 1 | Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.